Invivo Therapt: (OTCBB: NVIV)
$2.89
0.02 (0.70%)
Volume 148,054
May 17 03:58 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 2.83 - 2.90 |
| 52wk Low - High | 1.25 - 3.79 |
| Previous Close | 2.87 |
| Avg. Volume | 311,138 |
| Industry | MED PRODUCTS |
| Market Cap | 191.16 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | -0.02 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.20 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.20 |
| Current Quarter Estimate | -0.06 |
| Most Accurate Estimate | -0.06 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-13-2013 |
| EPS Last Year | -0.19 |
| Expected Earnings Growth | NA |
Company Description
InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.07 | |
|
| CYTOSORBENTS CP | CTSO | 0.12 | |
|
| TRANS1 INC | TSON | 1.70 | |
|
| ABAXIS INC | ABAX | 45.35 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| ALERE INC | ALR | 26.30 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
| BIO-RAD LABS -A | BIO | 116.02 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -0.19 |
| Sales | NA |
| Net Income | -12 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 23rd - Businesswire
May 17, 2013
InVivo Therapeutics Sponsors 8th Annual Working 2 Walk Spinal Cord Injury Symposium - Businesswire
May 16, 2013
InVivo Therapeutics Reports First Quarter 2013 Financial Results, Provides Business Update - Businesswire
May 9, 2013
InVivo Therapeutics Announces Call Notice for Exercise of Warrants and Partial Termination of Warrant Exchange Offer - Businesswire
May 3, 2013
InVivo Therapeutics Named a 2013 "Best Places to Work" Winner by Boston Business Journal - Businesswire
May 2, 2013
I InVivo Therapeutics Holdings Corp's CEO to speak at BNN-TV's 'The Close' on Monday - M2
Apr 29, 2013
InVivo Therapeutics' CEO Scheduled to Appear on FOX Business Network's "Varney & Company" - Businesswire
Apr 29, 2013
InVivo Therapeutics' CEO Scheduled to Appear on Business News Network's "The Close" in Canada - Businesswire
Apr 26, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 5.00 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 2 out of 72 |
